Chiusura precedente | 0,9000 |
Aperto | 0,9000 |
Denaro | 0,0000 |
Domanda | 4,8000 |
Prezzo d'esercizio | 110,00 |
Scadenza | 2024-08-16 |
Min-Max giorno | 0,9000 - 0,9000 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 6 |
More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapyAbout half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual health was negatively impacted by prior endocrine therapy (61%)Findings were presented in a poster at The Menopause Society 2023 Annual Meeting COLUMBUS, Ohio, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – Agreement provides a path forward for a product, if appro
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancerSecond poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it will present two post